LIfT BioSciences has entered into partnership with Kings College London's Cell Therapy Unit and Clinical Research Facility to research and develop its breakthrough LIfT Cell Therapy for Pancreatic Cancer.
The Cell Therapy Unit is the largest manufacturing facility of its kind in either academia or industry in Europe, with capacity to produce more than six final products simultaneously and a total of around a thousand therapies per year. The unit is financially supported through both the NHS and NIHR. This is a complex and sophisticated Good Manufacturing Practice (GMP) Unit built to the exacting standards required to meet the licensing requirements of the Medicines and Healthcare products Regulatory Agency (MHRA) for the manufacture of human cell and gene based therapies.
The Clinical Research Facility spans three floors with a further standalone unit. Each area has been designed and built to compliment the other in terms of ability to offer a unique and neutral space to carry out trials in a dedicated research setting.
As part of the arrangement Professor Farzin Farzaneh, an expert in Molecular Medicine and Cell Therapies leading the team at King’s College London, has joined LIfTBioSciences Advisory Board. Professor Farzaneh has been running GMP facilities for the production of cell and gene therapy based investigational medicinal products since 2001.
Alex Blyth, CEO, LIfT BioSciences commented that "the partnership builds on our strategy to partner with the best institutions in Europe to bring this breakthrough therapy to patients as fast and effectively as possible".